Trump will not include Medicare negotiation in drug pricing plan

Leo Vartorella - Print  | 

President Donald Trump's proposed drug pricing plan will not call for Medicare to negotiate pricing with drug manufacturers, despite Democratic support for the idea, according to The Hill.

While the plan will exclude provisions for Medicare to directly negotiate with pharmaceutical companies, there will reportedly be other measures to increase competition within Medicare.

"We're not calling for Medicare negotiation in the way that Democrats have called for," a White House official said, according to The Hill.

Though many Democrats support direct Medicare negotiation, the proposal would most likely garner little Republican support. Many of the blueprints outlined in President Trump's plan are expected to target pharmacy benefit managers, which have drawn criticism for their lack of transparency.

Other potential aspects of the proposal include ways to reduce "gaming" practices by drug companies that prevent generic drugs from entering the market and Medicare Part B reforms.

More articles on leadership and management:

Trump wants to slash $15B in spending, including on CHIP
Michael Dowling: 7 reasons organizations should be cultivating future nurse leaders
Carilion Clinic President and CEO Nancy Agee to head AHA board: 6 things to know

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.